Compare ENTA & AGD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENTA | AGD |
|---|---|---|
| Founded | 1995 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 374.6M | 318.4M |
| IPO Year | 2012 | 2006 |
| Metric | ENTA | AGD |
|---|---|---|
| Price | $13.16 | $12.49 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $20.40 | N/A |
| AVG Volume (30 Days) | ★ 199.8K | 95.5K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.93 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $102,814,000.00 | N/A |
| Revenue This Year | $7.76 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.48 | N/A |
| 52 Week Low | $5.88 | $10.25 |
| 52 Week High | $17.15 | $13.98 |
| Indicator | ENTA | AGD |
|---|---|---|
| Relative Strength Index (RSI) | 41.92 | 57.56 |
| Support Level | $13.00 | $12.19 |
| Resistance Level | $13.76 | $12.83 |
| Average True Range (ATR) | 0.72 | 0.21 |
| MACD | -0.13 | -0.02 |
| Stochastic Oscillator | 8.71 | 63.53 |
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
Aberdeen Global Dynamic Dividend Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current dividend income, more than 50% of which qualifies for the reduced federal income tax rate, as created by the Jobs and Growth Tax Relief Reconciliation Act of 2003. The fund also focuses on the long-term growth of capital as a secondary investment objective. The fund's portfolio holdings are in information technology, financials, health care, and consumer discretionary sectors, among others.